| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.15 | 0.0007 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.54 | 0.0008 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.002 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.003 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |